Regenxbio Stock News

RGNX announced promising safety and efficacy data from its SCS micro injector trial.

REGENXBIO Inc. (NASDAQ:RGNX)s share price gapped up prior to trading on Monday . The stock had previously closed at $30.47, but opened at $32.13. REGENXBIO shares last traded at $31.71, with a volume of 13 shares. A number of brokerages recently commented on RGNX. Roth Capital raised their target price on REGENXBIO from $15.00 to []

Wall Street brokerages predict that REGENXBIO Inc. (NASDAQ:RGNX) will post earnings per share (EPS) of $6.14 for the current quarter, according to Zacks. Two analysts have provided estimates for REGENXBIOs earnings. The lowest EPS estimate is $1.78 and the highest is $9.39. REGENXBIO reported earnings of ($1.24) per share in the same quarter last year, []

Brokerages expect REGENXBIO Inc. (NASDAQ:RGNX) to post $443.53 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for REGENXBIO’s earnings. The highest sales estimate is $495.60 million and the lowest is $391.45 million. REGENXBIO reported sales of $21.45 million during the same quarter last year, which would […]

Different market evaluation and appropriate data techniques are often used to compile and evaluate the data which is offered in this Hypercholesterolemia Treatment market report. In addition, we have an in-house information prediction model that forecasts product demand until 2027.

Everence Capital Management Inc. acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,140 shares of the biotechnology companys stock, valued at approximately $215,000. Several other hedge funds and other []

BioCardia (NASDAQ:BCDA) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent ratings for BioCardia and REGENXBIO, as provided by MarketBeat. []

Louisiana State Employees Retirement System increased its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 15.3% in the third quarter, Holdings Channel.com reports. The institutional investor owned 18,100 shares of the biotechnology companys stock after acquiring an additional 2,400 shares during the period. Louisiana State Employees Retirement Systems holdings in REGENXBIO were worth $759,000 at the end []

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

Prudential Financial Inc. cut its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 2.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 38,999 shares of the biotechnology companys stock after selling 1,131 shares during the quarter. Prudential Financial Inc.s holdings in REGENXBIO were worth $1,515,000 []

The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (Duchenne).  Duchenne is a genetic disorder

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been given a consensus recommendation of Buy by the ten brokerages that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average []

Related Stocks: IAC , ENTA , RGNX , IVV , WH , EOLS , IMCR , FCOB , MRSN , IMUX , BKCC , NEXI , HUM , GRA , ASND , NWHM , MUDS , BPY ,